How big is SAGE Therapeutics, Inc.?

As of Jun 18, SAGE Therapeutics, Inc. has a market capitalization of 571.13 million and reported net sales of 47.40 million with a net profit of -354.39 million over the latest four quarters. Shareholder's funds are 465.09 million, and total assets amount to 547.22 million.

As of Jun 18, SAGE Therapeutics, Inc. has a market capitalization of 571.13 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 47.40 million, while the sum of net profit for the same period is -354.39 million.<BR><BR>As of Dec 24, the shareholder's funds are reported at 465.09 million, and total assets amount to 547.22 million.

What does SAGE Therapeutics, Inc. do?

SAGE Therapeutics, Inc. is a micro-cap biotechnology company focused on pharmaceuticals, with recent net sales of $14 million and a net loss of $62 million. It has a market cap of $571.13 million and key metrics indicating it is currently unprofitable.

Overview: <BR>SAGE Therapeutics, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 14 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -62 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 571.13 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.03 <BR>Return on Equity: -81.01% <BR>Price to Book: 1.39<BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Should I buy, sell or hold SAGE Therapeutics, Inc.?

Is SAGE Therapeutics, Inc. overvalued or undervalued?

As of February 24, 2022, SAGE Therapeutics, Inc. is considered risky and overvalued due to poor financial metrics, including a price-to-book ratio of 1.05, a negative return on equity of -81.01%, and underperformance compared to its peer Ironwood Pharmaceuticals and the S&P 500.

As of 24 February 2022, the valuation grade for SAGE Therapeutics, Inc. has moved from attractive to risky, indicating a significant deterioration in its financial outlook. The company appears to be overvalued given its current financial metrics, particularly with a price-to-book ratio of 1.05 and a negative return on equity of -81.01%. Additionally, the EV to EBITDA ratio stands at -0.02, further highlighting the company's struggles.<BR><BR>When compared to its peer, Ironwood Pharmaceuticals, Inc., which has a P/E ratio of 13.85 and an EV to EBITDA of 6.53, SAGE's metrics suggest it is not performing favorably within its industry. The stock has underperformed against the S&P 500 over the past year, with a return of -11.07% compared to the index's 17.14%, reinforcing the notion that SAGE is currently overvalued.

Is SAGE Therapeutics, Inc. technically bullish or bearish?

As of July 18, 2025, SAGE Therapeutics has a mildly bullish technical trend, with mixed indicators showing bullish momentum on daily and weekly charts but bearish signals in the weekly RSI and Dow Theory, while it has underperformed the S&P 500 recently but significantly outperformed year-to-date.

As of 18 July 2025, the technical trend for SAGE Therapeutics, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. However, the weekly RSI is bearish, indicating some weakness in momentum. The Bollinger Bands show a mildly bullish stance on the weekly chart but are mildly bearish on the monthly chart. Moving averages are bullish on the daily timeframe, while the KST is bullish weekly and mildly bullish monthly. Dow Theory indicates a bearish stance on both weekly and monthly timeframes. The On-Balance Volume is mildly bearish weekly with no trend monthly.<BR><BR>In terms of performance, SAGE has underperformed the S&P 500 over the past week and month, with returns of -1.36% and -4.41% compared to 1.05% and 2.33% for the index, respectively. However, year-to-date, SAGE has significantly outperformed the S&P 500 with a return of 59.85% versus 12.22%. Overall, the current technical stance is mildly bullish, but with notable bearish signals in the weekly RSI and Dow Theory.